Semaglutide
Semaglutide (Ozempic/Wegovy)
The most well-known GLP-1 receptor agonist, approved for both diabetes and obesity. Backed by extensive clinical data and the largest user base of any weight loss medication.
Key Research
Peer-Reviewed Evidence • 3 Citations
Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH et al.•N Engl J Med•2021•PMID: 33567185
Key Finding: Semaglutide 2.4mg achieved 14.9% mean body weight reduction vs 2.4% with placebo over 68 weeks in non-diabetic adults.
View on PubMedSemaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)
Marso SP et al.•N Engl J Med•2016•PMID: 27633186
Key Finding: Semaglutide reduced major cardiovascular events by 26% in type 2 diabetes patients, establishing cardioprotective benefits.
View on PubMedOral semaglutide versus empagliflozin in patients with type 2 diabetes (PIONEER 2)
Rodbard HW et al.•Diabetes Care•2019•PMID: 31530667
Key Finding: Oral semaglutide provided superior HbA1c reduction compared to empagliflozin, demonstrating efficacy of oral GLP-1 delivery.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📊 Evidence by Outcome
STEP trials demonstrated 15-17% weight loss. Largest body of evidence for any weight loss drug.
20 studies • Consistency: High • Effect: Large
SELECT trial showed 20% reduction in major cardiovascular events independent of diabetes status.
8 studies • Consistency: High • Effect: Large
Gold standard for type 2 diabetes management.
15 studies • Consistency: High • Effect: Large
👥 Community Insights
Lost 18kg on Ozempic. Food noise completely gone. Life-changing.
Community member • Dubai• Verified
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.